Continuous Jugular Venous Oxygen Saturation (SjO2) Measurement After Cardiac Arrest
Launched by BYRON DRUMHELLER · Jul 15, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method to measure the oxygen levels in the blood leaving the brain of patients who have been successfully resuscitated after a cardiac arrest but remain in a coma. After a cardiac arrest, the brain can be at risk for further injury, and understanding how well it is receiving oxygen is crucial for treatment. The researchers want to see if a special catheter, which can continuously measure this oxygen level without needing to take blood samples frequently, is accurate compared to the standard method that requires sending blood to a lab for testing.
To participate in this study, individuals must be at least 18 years old and have been resuscitated from cardiac arrest, remaining comatose (not responding) for at least 30 minutes. However, those with certain conditions, like traumatic brain injuries or severe instability, will not be eligible. If someone joins the trial, they can expect to have the new catheter placed to monitor their brain's oxygen levels, while their health will be closely observed by a specialized medical team. This research aims to provide quicker and more accurate information about brain health in patients recovering from cardiac arrest.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Adults (\>=18 years old) resuscitated from out-of-hospital or in-hospital cardiac arrest who remain comatose (motor Glasgow coma scale \<=4) for at least 30 minutes when examined off sedation/neuromuscular blockade.
- Exclusion Criteria:
- • Cardiac arrest due to traumatic brain injury, intracranial bleeding, or ischemic stroke
- • Cervical spine fracture
- • Need for immediate prone positioning for severe hypoxemic respiratory failure
- • Marked hemodynamic instability precluding priority of any neuromonitoring (multiple recurrent cardiac arrests, norepinephrine equivalents \> 1.5 mcg/kg/min)
- • Moribund neurological status based upon initial clinical, radiographic and historical assessment (e.g. diffuse cerebral edema or herniation on head computed tomography)
- • Pregnancy
- • Prisoners
About Byron Drumheller
Byron Drumheller is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on integrity and scientific rigor, Byron Drumheller oversees a diverse portfolio of clinical studies across various therapeutic areas. The organization collaborates with leading researchers and healthcare professionals to ensure the highest standards of quality and compliance, fostering a culture of transparency and collaboration. Through its strategic partnerships and commitment to patient-centered research, Byron Drumheller aims to drive the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Byron Drumheller, MD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported